Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nyxoah S.A.NASDAQ: NYXH
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -€14.63M, compared with -€21.2M a year earlier. Trailing-twelve-month EBITDA was -€77.16M.
Context
- EBITDA amounted to 827.4% of revenue in FY2025, down 361.9 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -€33.19M (+60.0%) for the fiscal year ending Dec 2026, a step up from the -54.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€14.63M+32.0% QoQ
- Last fiscal yearDec 2025
- -€82.9M-54.2% YoY
- LTMMar 2026
- -€77.16M-21.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +31.0% | -53.8% | -84.8 pp |
| 1 year | -54.2% | +60.0% | +114.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- (82.9M) EUR
- Year-over-year change
- -54.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.9M) | -54.2% |
| FY2024 | 2024-12-31 | (53.77M) | -27.8% |
| FY2023 | 2023-12-31 | (42.08M) | -50.9% |
| FY2022 | 2022-12-31 | (27.89M) | -23.4% |
| FY2021 | 2021-12-31 | (22.59M) | — |
EBITDA vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -21.4% is the 7th highest of 10, against a peer median of +9.1%.
- EBITDA amounts to 472.8% of revenue for NYXH, versus a peer median of 50.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.36M USD | -9.1% | -15.0% | 43.6% | |
| LTM Mar 2026 | -$1.47M USD | +67.9% | — | 3.4% | |
| LTM Mar 2026 | -$25.7M USD | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$33.82M USD | +24.4% | — | 117.0% | |
| LTM Mar 2026 | -$51.68M USD | +9.1% | — | 45.4% | |
| LTM Mar 2026 | -$62.94M USD | -39.6% | — | — | |
| LTM Mar 2026 | -$63.7M USD | -188.7% | — | 56.4% | |
| LTM Mar 2026 | -$75.72M USD | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -€77.16M EUR | -21.4% | — | 472.8% | |
| LTM Mar 2026 | -$110.64M USD | -31.7% | — | 17902.8% | |
| Peer median (excluding NYXH) | — | +9.1% | -15.0% | 50.9% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 852K | 3.08M | 4.35M | 4.52M | 10.02M |
| Cost of Revenue | 303K | 1.15M | 1.66M | 1.55M | 3.69M |
| Gross Profit | 549K | 1.93M | 2.69M | 2.97M | 6.33M |
| Gross Margin | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| Research & Development | 5.95M | 15.86M | 27.66M | 34.33M | 42.82M |
| Selling, General & Admin | 11.11M | 18.86M | 20.65M | 28.46M | 46.44M |
| Operating Expenses | 26.79M | 34.43M | 47.79M | 61.78M | 89.27M |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 764K | 4.48M |
| EBITDA | (22.59M) | (27.89M) | (42.08M) | (53.77M) | (82.9M) |
| EBITDA Margin | -2651.5% | -904.2% | -967.8% | -1189.2% | -827.4% |
| Operating Income | (26.24M) | (32.5M) | (45.1M) | (58.81M) | (82.94M) |
| Operating Margin | -3080.0% | -1053.8% | -1037.3% | -1300.8% | -827.8% |
| Interest Income | 1K | 372K | 2.57M | 2.5M | 1.83M |
| Interest Expense | 386K | 237K | 1.21M | 1.9M | 1.69M |
| Other Income / Expenses | 1.6M | 2.44M | 445K | 2.38M | (6.13M) |
| Income Before Tax | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (89.08M) |
| Pre-Tax Margin | -2891.9% | -974.6% | -1027.1% | -1248.2% | -889.0% |
| Income Tax Expense | 2.98M | 1.17M | (1.45M) | 2.8M | 1.01M |
| Net Income | (27.62M) | (31.23M) | (43.21M) | (59.24M) | (90.09M) |
| Net Margin | -3241.7% | -1012.5% | -993.8% | -1310.2% | -899.1% |
| EPS (Basic) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| EPS (Diluted) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| Weighted Avg Shares | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
| Weighted Avg Shares (Diluted) | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.